Physician profile
Richard E Campbell
NPI 1114681970
$1,300.52
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.79 · 2023: $575 · 2024: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $476.47 | 2023-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $135.24 | 2023-2024 | Breztri, Tezspire |
| Regeneron Healthcare Solutions, INC. | $103.65 | 2023-2024 | Dupixent |
| Abbvie INC. | $100.34 | 2024 | |
| Philips North America LLC | $90.12 | 2023-2024 | (Ak6) Vest Therapy |
| Genzyme Corporation | $88.82 | 2023-2024 | |
| Amgen INC. | $62.67 | 2023-2024 | Tezspire |
| Jazz Pharmaceuticals INC. | $48.12 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.26 | 2023 | Aralast |
| Genentech USA, INC. | $31.14 | 2022-2024 | Xolair |
| Harmony Biosciences LLC | $29.27 | 2023-2024 | Wakix |
| Merck Sharp & Dohme LLC | $27.61 | 2023 | |
| Electromed, INC. | $18.38 | 2023 | Smartvest |
| Mylan Specialty L.P. | $16.68 | 2024 | Yupelri |
| Vapotherm INC | $16.58 | 2024 | Vapotherm |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.17 | 2024 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.